A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.

Adult Animals Bevacizumab / pharmacology Cell Line, Tumor Disease Models, Animal Drug Resistance, Neoplasm / drug effects Female Furans / pharmacology Humans Ketones / pharmacology Mice Phthalazines / pharmacology Piperazines / pharmacology Triple Negative Breast Neoplasms / drug therapy Vinorelbine / pharmacology Xenograft Model Antitumor Assays
PDOX TNBC eribulin matrix-producing breast carcinoma nude mice olaparib patient-derived orthotopic xenograft regression resistance triple-negative breast cancer

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
May 2020
Historique:
received: 25 03 2020
revised: 06 04 2020
accepted: 14 04 2020
entrez: 6 5 2020
pubmed: 6 5 2020
medline: 19 5 2020
Statut: ppublish

Résumé

Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triple-negative breast cancer (TNBC). In this study, we determined drug sensitivity for a triple-negative MPBC, without BRCA mutations, in a patient-derived orthotopic xenograft (PDOX) model. The MPBC PDOX model was established in the left 2 The MPBC PDOX model was resistant to olaparib (p=0.22). The MPBC PDOX model treated with bevacizumab and vinorelbine showed significantly suppressed tumor growth compared to the untreated group (p=0.005 and 0.002, respectively). However, only eribulin regressed the tumor (p=0.0001). Eribulin was more effective than olaparib (p=0.0001), bevacizumab (p=0.0025) and vinorelbine (p=0.0061). Eribulin has clinical potential as treatment for triple-negative MPBC patients that are resistant to a PARP inhibitor such as olaparib.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triple-negative breast cancer (TNBC). In this study, we determined drug sensitivity for a triple-negative MPBC, without BRCA mutations, in a patient-derived orthotopic xenograft (PDOX) model.
MATERIALS AND METHODS METHODS
The MPBC PDOX model was established in the left 2
RESULTS RESULTS
The MPBC PDOX model was resistant to olaparib (p=0.22). The MPBC PDOX model treated with bevacizumab and vinorelbine showed significantly suppressed tumor growth compared to the untreated group (p=0.005 and 0.002, respectively). However, only eribulin regressed the tumor (p=0.0001). Eribulin was more effective than olaparib (p=0.0001), bevacizumab (p=0.0025) and vinorelbine (p=0.0061).
CONCLUSION CONCLUSIONS
Eribulin has clinical potential as treatment for triple-negative MPBC patients that are resistant to a PARP inhibitor such as olaparib.

Identifiants

DOI: 10.21873/anticanres.14221 PMID: 32366395
pubmed: 32366395
pii: 40/5/2509
doi: 10.21873/anticanres.14221
doi:

Substances chimiques

Furans 0
Ketones 0
Phthalazines 0
Piperazines 0
Bevacizumab 2S9ZZM9Q9V
eribulin LR24G6354G
Vinorelbine Q6C979R91Y
olaparib WOH1JD9AR8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2509-2514

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Jun Yamamoto (J)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.
Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Takuya Murata (T)

Department of Obstetrics and Gynecology, Kawasaki Medical School, Okayama, Japan.

Yoshihiko Tashiro (Y)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Takashi Higuchi (T)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Norihiko Sugisawa (N)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Hiroto Nishino (H)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Sachiko Inubushi (S)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Y U Sun (YU)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Hyein Lim (H)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Kentaro Miyake (K)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.
Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Atsushi Hongo (A)

Department of Obstetrics and Gynecology, Kawasaki Medical School, Okayama, Japan.

Tsunehisa Nomura (T)

Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Japan.

Wataru Saitoh (W)

Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Japan.

Takuya Moriya (T)

Department of Pathology, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Hirokazu Tanino (H)

Breast Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.

Chihiro Hozumi (C)

AntiCancer Japan Inc, Narita, Japan.

Michael Bouvet (M)

Department of Surgery, University of California, San Diego, CA, U.S.A.

Shree Ram Singh (SR)

Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A. all@anticancer.com singhshr@mail.nih.gov endoit@yokohama-cu.ac.jp.

Itaru Endo (I)

Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan all@anticancer.com singhshr@mail.nih.gov endoit@yokohama-cu.ac.jp.

Robert M Hoffman (RM)

AntiCancer Inc, San Diego, CA, U.S.A. all@anticancer.com singhshr@mail.nih.gov endoit@yokohama-cu.ac.jp.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Eucaryotes › Animaux › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Bévacizumab › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Furanes › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Composés chimiques organiques › Cétones › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridazines › Phtalazines › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipérazines › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Tumeurs du sein triple-négatives › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Indolizine › Indolizidines › Alcaloïdes indoliques › Alcaloïdes formés par condensation de sécologanine et de tryptamine › Alcaloïdes de Vinca › Vinorelbine › A Triple-negative Matrix-producing Breast...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › A Triple-negative Matrix-producing Breast...